Latest news with #MALS
Daily Mirror
28-07-2025
- Health
- Daily Mirror
'I lost 13kg in six weeks as rare condition left me starving to death'
Kristina Bayus-Roszak, 29, lost 30lbs in just six weeks when she suddenly fell ill A young woman wasting away due to a rare condition was forced to travel 4,000 miles to save her life. Kristina Bayus-Roszak, 29, shed 30lbs (more than 13kg) in just six weeks when she suddenly became unwell. She endured crippling symptoms including relentless vomiting, stomach pain and nausea until medics finally identified her condition as median arcuate ligament syndrome (MALS), also known as Dunbar syndrome. This incredibly rare illness affects just two in every 100,000 people, according to estimates. "The doctor told me I would have maybe 18 to 22 months to live if I didn't have surgery," Kristina, a digital marketing specialist, told What's The Jam. "Mine was one of the worst cases they'd ever seen. My body was shutting down. I was slowly starving to death." Dunbar syndrome takes place when the artery delivering blood to the stomach becomes squeezed. Frail and desperate, Kristina, from Cleveland, US, recently embarked on a life-saving journey to Leipzig in Germany. She maintains she couldn't undergo the operation in America because there are no surgeons who can operate on multiple compressions at one time. Once overseas, she received an advanced ultrasound scan and was diagnosed with five more extremely rare disorders, which are all characterised by abdominal vascular compressions. Kristina's kidney had also blackened from the shortage of blood flow, and within a week, she was transferred to Düsseldorf for specialist surgery. She said: "My family were very supportive. My husband Kyle made the journey with me and I could not have done it without him. "My friends and family also did multiple fundraisers and a GoFundMe to help me get there. I wouldn't be where I am today without their love and support." The life-saving procedure took more than eight hours, with Kristina's surgeon uncovering that she also had an abdominal aneurysm that would have burst within a month if left undetected. It has now been almost two years since the surgery, which is the estimated recovery time for a procedure of this kind. Thankfully, Kristina is finally nearing the end of her gruelling journey. She explained: "My surgeon is nothing short of extraordinary. I am doing so much better and I have the ability to eat once more, which I'll never take for granted again. "I have also slowly gained weight and my organ health has improved substantially. I'm also no longer in chronic pain and can get back to doing the things I love, like hiking. I have my life back." Kristina has opened up about her ordeal, hoping it might assist others facing similar challenges. She continued: "I am so proud of my ability to persevere through this. There was nothing easy about travelling to a foreign country for a major surgery. "I wasn't even sure if I'd survive. I did survive though and while it was the hardest thing I've ever dealt with I made it through and I am a stronger and a better person for it. "I wish people knew how incredibly strong those with vascular compressions and rare diseases are. Research and treatment options are limited and half of the medical professionals don't even understand. "My goal now is to bring awareness and help to so many others suffering from these debilitating and even deadly rare diseases. We fight every day for care even when we are dealing with the cruellest pain and symptoms. "If you have someone in your life struggling with a chronic illness, rare or not, please give them some grace. Remind them they are loved and they are worthy. Understanding and kindness go such a long way."
Yahoo
13-05-2025
- Business
- Yahoo
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
News Summary Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass., May 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage using Empower Software. Additionally, this advancement will simplify the process and digital footprint of acquiring and submitting compliant data to regulatory authorities – from biologics development through QC – saving customers up to six months of software validation time. Empower Software is the industry's most established and compliant-ready chromatography data system (CDS), widely adopted globally and used to submit data for more than 80% of novel drugs to regulatory authorities.4 The new integration unlocks the ability to use MALS techniques in quality control for biotherapeutics, improving efficiency and Good Manufacturing Practices (GMP) readiness, while reducing end-user training in compliant settings. "Today's launch of Empower for Multi-Angle Light Scattering Detectors underscores our commitment from the Wyatt acquisition to integrate advanced analytical technologies into our Empower CDS ecosystem," said Dr. Udit Batra, President & CEO, Waters Corporation. "Specifically, MALS supported on Empower Software reveals high molecular weight species that are not visible to other detectors – reducing the risk of erroneous results in biotherapeutic quality control. By combining the strengths of compliant software with deep analytical light scattering instrumentation, we are providing customers with a unified solution that enhances productivity and data accuracy – ultimately supporting high-volume QC testing to ensure the safety of life-saving biologic therapies for patients." The integration of the DAWN™, miniDAWN™, and OptiLab™ Detectors will enable the measurement of more critical quality attributes of peptides and proteins in a single run, reducing analysis time by 20% and providing earlier insights into the stability, safety, and efficacy of biologics. "As a Contract Development and Manufacturing Organization (CDMO), we anticipate that MALS on Empower Software will enhance our service offerings," said William Wittbold, Senior Director of Operations, at Pace Analytical. "The detailed MALS data is essential for understanding complex biotherapeutics. Combined with the reliability of Empower Software, we believe this integration will deliver exceptional value to our customers, ensuring our drug development partners receive the highest quality results." The capability to integrate the DAWN, miniDAWN, and OptiLab Detectors with Empower Software will be available for peptide and protein workflows in July 2025. Learn more by visiting our product page. Additional Resources - Learn more about the MALS integration with Empower Software. - Follow and connect with Waters LinkedIn, Twitter, and Facebook. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Waters, Empower, DAWN, miniDAWN, OptiLab, and Wyatt Technology are trademarks of Waters Technologies Corporation. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 1. In a recent survey of 50 MALS users, responding to the question "How long does it typically take you to validate new software in a GxP lab," the average time was reported as 6 months since it is one software instead of two. 2. In a recent survey of 50 MALS users, responding to the question "How much time, as a percentage of total working time, would you save on average if you could use your primary CDS software (LC software) for MALS data analysis," the average time saving was reported as 20%. 3. White paper WP1615: "SEC-MALS for absolute biophysical characterization" describes the challenges associated with determining basic physical properties of biologics in solution, and provides examples of how multi-angle light scattering can reduce the occurrence of erroneous results prevalent in relative measurement techniques. MALS provides absolute results from first principles, avoiding errors of relative measures, and is independent of retention time, reference materials, and column interactions. 4. Presented at the J.P. Morgan 43rd Annual Healthcare Conference. According to internal analysis, ~80% of the drugs filed with the FDA, EMA, and China National Medical Products Administration (NMPA) in 2023 were done so using Empower Software. Source: Waters data and estimates. View original content: SOURCE Waters Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
News Summary Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass., May 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage using Empower Software. Additionally, this advancement will simplify the process and digital footprint of acquiring and submitting compliant data to regulatory authorities – from biologics development through QC – saving customers up to six months of software validation time. Empower Software is the industry's most established and compliant-ready chromatography data system (CDS), widely adopted globally and used to submit data for more than 80% of novel drugs to regulatory authorities.4 The new integration unlocks the ability to use MALS techniques in quality control for biotherapeutics, improving efficiency and Good Manufacturing Practices (GMP) readiness, while reducing end-user training in compliant settings. "Today's launch of Empower for Multi-Angle Light Scattering Detectors underscores our commitment from the Wyatt acquisition to integrate advanced analytical technologies into our Empower CDS ecosystem," said Dr. Udit Batra, President & CEO, Waters Corporation. "Specifically, MALS supported on Empower Software reveals high molecular weight species that are not visible to other detectors – reducing the risk of erroneous results in biotherapeutic quality control. By combining the strengths of compliant software with deep analytical light scattering instrumentation, we are providing customers with a unified solution that enhances productivity and data accuracy – ultimately supporting high-volume QC testing to ensure the safety of life-saving biologic therapies for patients." The integration of the DAWN™, miniDAWN™, and OptiLab™ Detectors will enable the measurement of more critical quality attributes of peptides and proteins in a single run, reducing analysis time by 20% and providing earlier insights into the stability, safety, and efficacy of biologics. "As a Contract Development and Manufacturing Organization (CDMO), we anticipate that MALS on Empower Software will enhance our service offerings," said William Wittbold, Senior Director of Operations, at Pace Analytical. "The detailed MALS data is essential for understanding complex biotherapeutics. Combined with the reliability of Empower Software, we believe this integration will deliver exceptional value to our customers, ensuring our drug development partners receive the highest quality results." The capability to integrate the DAWN, miniDAWN, and OptiLab Detectors with Empower Software will be available for peptide and protein workflows in July 2025. Learn more by visiting our product page. Additional Resources - Learn more about the MALS integration with Empower Software. - Follow and connect with Waters LinkedIn, Twitter, and Facebook. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Waters, Empower, DAWN, miniDAWN, OptiLab, and Wyatt Technology are trademarks of Waters Technologies Corporation. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 1. In a recent survey of 50 MALS users, responding to the question "How long does it typically take you to validate new software in a GxP lab," the average time was reported as 6 months since it is one software instead of two. 2. In a recent survey of 50 MALS users, responding to the question "How much time, as a percentage of total working time, would you save on average if you could use your primary CDS software (LC software) for MALS data analysis," the average time saving was reported as 20%. 3. White paper WP1615: "SEC-MALS for absolute biophysical characterization" describes the challenges associated with determining basic physical properties of biologics in solution, and provides examples of how multi-angle light scattering can reduce the occurrence of erroneous results prevalent in relative measurement techniques. MALS provides absolute results from first principles, avoiding errors of relative measures, and is independent of retention time, reference materials, and column interactions. 4. Presented at the J.P. Morgan 43rd Annual Healthcare Conference. According to internal analysis, ~80% of the drugs filed with the FDA, EMA, and China National Medical Products Administration (NMPA) in 2023 were done so using Empower Software. Source: Waters data and estimates. View original content: SOURCE Waters Corporation
